March 22, 2024 / Care

ITF Therapeutics Shares Update on DUVYZAT™ Following FDA Approval

Following the FDA’s approval of DUVYZAT™ (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the company responsible for producing and marketing DUVYZAT™ in the United States, today shared an update on the drug and related resources.

ITF Therapeutics has launched the DUVYZAT™ website, which provides Indication and Important Safety Information, a comprehensive list of FAQs, full Prescribing Information, a Patient Medication Guide, as well as an opportunity for individuals to sign up for updates on DUVYZAT™.

ITF Therapeutics has indicated that they expect DUVYZAT™ to be available in Q3 of 2024 and that the company will be hosting informational webinars for members of the Duchenne community in the near future.


PPMD has requested to host a webinar with ITF Therapeutics on Wednesday, March 27th at 1:00 PM ET to provide the community with an opportunity to meet members of the ITF Therapeutics team to learn more about their organization and next steps to support the availability of DUVYZAT™. Register now and submit your questions in advance here.

Access PPMD’s resource of FAQs surrounding the approval of DUVYZAT™ and what this means, including questions on eligibility and access here.

Join Our Mailing List